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Arm swing responsiveness to dopaminergic medication in
Parkinson’s disease depends on task complexity
Elke Warmerdam1,2✉, Robbin Romijnders1,2, Clint Hansen 1, Morad Elshehabi1, Milan Zimmermann3,4, Florian G. Metzger5,6,7,
Anna-Katharina von Thaler3, Daniela Berg1,3, Gerhard Schmidt2 and Walter Maetzler 1
The evidence of the responsiveness of dopaminergic medication on gait in patients with Parkinson’s disease is contradicting. This
could be due to differences in complexity of the context gait was in performed. This study analysed the effect of dopaminergic
medication on arm swing, an important movement during walking, in different contexts. Forty-five patients with Parkinson’s
disease were measured when walking at preferred speed, fast speed, and dual-tasking conditions in both OFF and ON medication
states. At preferred, and even more at fast speed, arm swing improved with medication. However, during dual-tasking, there were
only small or even negative effects of medication on arm swing. Assuming that dual-task walking most closely reflects real-life
situations, the results suggest that the effect of dopaminergic medication on mobility-relevant movements, such as arm swing,
might be small in everyday conditions. This should motivate further studies to look at medication effects on mobility in Parkinson’s
disease, as it could have highly relevant implications for Parkinson’s disease treatment and counselling.
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INTRODUCTION
Dopaminergic medication is the most common treatment for
people with Parkinson’s disease. It is highly effective in improving
Parkinson’s disease-related symptoms such as bradykinesia,
rigidity, and tremor, as has been shown, for example, with the
unified Parkinson’s disease rating scale (UPDRS), its revised version
(MDS-UPDRS), and other established clinical scales1–4.
However, contradicting results were found concerning the
effect of dopaminergic medication on gait deficits associated with
Parkinson’s disease. Only gait speed, stride length, and stride
velocity have consistently shown an increase with medication in
multiple studies with different disease severities2,5,6, study
protocols2,7–10, and measurement equipments2,5,8,10–13. The
effects of dopaminergic medication on other gait parameters
are not entirely clear. For example, although one relatively large
study found an increased cadence (steps per minute) with
dopaminergic medication5, four others—with comparable cohort
characteristics—did not7,8,10,13. One study found a decrease
instance time11 but another study—again with comparable cohort
characteristics—did not5. Contradicting results were also found for
double limb support (for example, one study found no significant
change5, where other studies found a decrease with medica-
tion10,11,14) and gait variability (three studies found no significant
change8,11,15, four studies found a decrease with medica-
tion8,9,13,15). Similarly, there are contradicting results concerning
the effect of dopaminergic medication on arm swing parameters
in Parkinson’s disease. For example, arm swing asymmetry only
decreased with medication in one16 but not in another study5.
Brain activity differs with the complexity of walking tasks and
with neurological pathologies17. We therefore hypothesize that at
least some of the above-mentioned contradicting results may be
explained by differences in the context where the respective
walking task is performed. This hypothesis is, at least indirectly,
supported by studies that found an effect of task complexity on
the effect of medication on certain gait parameters (e.g., gait
speed18 and stride time variability19). Moreover, two studies
reported a change in the difference of walking parameters
between Parkinson’s disease and controls, depending on the
walking paradigm (between preferred and fast walking condition:
gait speed, swing velocity, step time, and swing time; between
preferred and dual-task condition: stride length and percentage
swing time20,21). These differences in the response of mobility
patterns to different stimuli and demands could have highly
relevant implications for Parkinson’s disease treatment and
counselling, as human behavior depends on the use of highly
diverse mobility strategies22.
We therefore measured in this study the effect of dopaminergic
medication on a specific movement, i.e., arm swing, during
preferred, fast and dual-task walking. We then compared the delta
of medication ON minus OFF, of different arm swing parameters
between the different walking conditions. We chose arm swing
because arm swing (i) is relatively easy and very reliable to
measure23, (ii) is influenced by cognitive dual-tasks24–26 that occur
regularly in daily life, (iii) is influenced by Parkinson’s disease
(smaller arm swing amplitudes and more asymmetry compared to
controls)27–29, and (iv) is influenced by dopaminergic medication.
For example, arm swing amplitude and angular velocity increase
with medication5,16,30.
RESULTS
Changes in arm swing with dopaminergic medication
Demographics and task performance of the included Parkinson’s
disease patients are provided in Tables 1 and 2.
The following changes of arm swing parameters due to
dopaminergic medication were significant (see also Fig. 1 and
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Supplementary Table 1). Main amplitude and peak angular
velocity increased with medication in the preferred and fast
walking condition, but not in the dual-task condition. Amplitude
asymmetry decreased with medication in the preferred and dual-
task conditions, but not at fast speed. Arm swing coordination
only increased in the fast walking condition. Regularity improved
with medication only in the preferred condition. The sideways
amplitude decreased with medication during the preferred and
fast walking condition, but increased during the dual-task
condition.
Cognitive performance
Cognitive performance as measured with subtractions per minute
improved with medication during the single-task (P= 0.012), but
not during the dual-task. The responsiveness to dopaminergic
medication was significantly different between the single-task and
dual-task (P= 0.005; Fig. 2). Moreover, cognitive dual-task costs
were significantly different per medication state (P= 0.027),
−29 % in OFF state and −12 % in ON state.
Responsiveness of arm swing to dopaminergic medication
The degree of responsiveness of respective arm swing parameters
to dopaminergic medication are shown in Fig. 2 for the 33
participants with a complete dataset. At preferred speed, the
responsiveness to dopaminergic medication was moderate for
amplitude asymmetry and small for all other arm swing
parameters. At fast speed, the responsiveness to medication was
large for main amplitude, peak angular velocity, coordination, and
sideways amplitude (decrease), small for amplitude asymmetry,
and negligible for regularity. The responsiveness to medication
was small for the cognitive single-task. In the dual-task condition,
the responsiveness to dopaminergic medication was moderate for
amplitude asymmetry and sideways amplitude (increase), small for
regularity, coordination, and cognitive performance, and negligi-
ble for main amplitude and peak angular velocity.
The following responses of arm swing parameters to dopami-
nergic medication were significantly different across the different
walking conditions in Parkinson’s disease (special characters in Fig.
2 and Supplementary Table 2): In the fast walking condition, main
amplitude, peak angular velocity, coordination, and sideways
amplitude were significantly more responsive (i.e., better) and
asymmetry was significantly less responsive (i.e., worse) than in
the preferred walking condition. Regularity was not significantly
different between these two conditions. In the dual-task walking
condition, main amplitude, regularity, and sideways amplitude
were significantly less responsive (i.e., worse) than in the preferred
walking condition. Peak angular velocity, amplitude asymmetry
and coordination were not significantly different between these
two conditions. In the dual-task walking condition, amplitude
asymmetry was significantly more responsive (i.e., better) and
main amplitude, peak angular velocity, coordination, sideways
amplitude, and cognitive performance were significantly less
responsive (i.e., worse) than in the fast walking condition.
Regularity was not significantly different between these two
conditions.
Correlations with the medication-induced changes in arm
swing
Almost none of the ON-OFF changes in arm swing parameters
correlated with any ON-OFF changes of the MDS-UPDRS (part
three total score and subscores). The only exceptions were
sideways amplitude and MDS-UPDRS rigidity subscore during the
preferred speed condition (P= 0.018), as well as coordination of
arm swing and postural instability and gait disorder score (PIGD)
during the dual-task walking condition (P= 0.027; Table 3). Several
of the ON-OFF changes in the arm swing parameters correlated
with the Levodopa equivalent daily dose (LEDD). At preferred
speed, main amplitude, peak angular velocity and coordination
correlated with LEDD (P= 0.005, P= 0.004, P= 0.015, respectively;
Table 3). At fast speed, arm swing asymmetry correlated
negatively with LEDD (P= 0.001). However, during the dual-
tasking condition, none of the ON-OFF changes of the arm swing
parameters correlated significantly with the LEDD.
Table 1. Demographics and disease characteristics (mean ± standard
deviation (range)) of the participants.
Characteristics Participants with Parkinson’s disease
n (male) 45 (30)
age [years] 65 ± 9 (46–84)
height [m] 1.73 ± 0.11 (1.55–1.93)
weight [kg] 77 ± 13 (53–107)
MoCA (0–30) 27 ± 2 (20–30)
Hoehn & Yahr (1–5) 2.0 ± 0.5 (HY1= 5, HY1.5= 2, HY2= 32,
HY2.5= 2, HY3= 4)
Disease duration [years] 5 ± 3 (1–10)
Levodopa equivalent
dose [mg]
523 ± 379 (155–1630)
MDS-UPDRS III (0–132) 21 ± 9 (6–61)
MDS-UPDRS III motor part of the Movement Disorders Society-sponsored
revision of the unified Parkinson’s disease rating scale.
Table 2. Performance (mean ± standard deviation (range)) of the participants.
Parameters OFF medication ON medication
Preferred gait speed [m/s] 1.34 ± 0.22 (0.88–1.87) 1.39 ± 0.19 (0.95–1.78)
Fast gait speed [m/s] 1.68 ± 0.25 (1.23–2.17) 1.75 ± 0.26 (1.26–2.52)
Dual-task gait speed [m/s] 1.29 ± 0.27 (0.68–1.80) 1.34 ± 0.27 (0.73–2.13)
Number of arm swings in preferred condition 87 ± 17 (51–128) 88 ± 18 (36–138)
Number of arm swings in fast condition 86 ± 17 (36–122) 86 ± 17 (51–130)
Number of arm swings in dual-task condition 89 ± 31 (35–231) 81 ± 16 (43–116)
Subtractions in single-task condition [n/min] 21 ± 13 (6–60) 23 ± 13 (4–46)
Subtractions in dual-task condition [n/min] 24 ± 12 (4–50) 22 ± 11 (9–61)
Subtraction mistakes in single-task condition [n/min] 1 ± 2 (0–9) 1 ± 2 (0–5)
Subtraction mistakes in dual-task condition [n/min] 2 ± 2 (0–8) 1 ± 3 (0–9)
MoCA Montreal cognitive assessment.
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This study shows that the effect of dopaminergic medication on
arm swing is substantially influenced by the context in which
patients with Parkinson’s disease walk. Arm swing during walking
improved with dopaminergic medication at preferred walking
speed, and it improved even more during fast walking at least for
some parameters (main amplitude, peak angular velocity,
coordination, and sideways amplitude). However, the responsive-
ness of dopaminergic medication on arm swing changed
drastically by adding a cognitive dual-task to walking compared
to preferred and fast walking only, respectively. In the dual-task
walking condition, the responsiveness to dopaminergic medica-
tion was low for most arm swing parameters, and sideways
amplitude got even worse. Only amplitude asymmetry improved,
because the amplitude of the more affected arm increased, while
the amplitude of the less affected arm decreased, reducing the
difference between both arms (Supplementary Fig. 1). A different
response to medication in the more and the less affected side was
only seen for amplitude and peak angular velocity during the
dual-task condition. We suggest that the talking out loud provides
rhythmical stimulation that could have a positive effect on the
coordination between both arms causing a more symmetrical arm
swing pattern. The correlations between the change in arm swing
parameters with dopaminergic medication and the LEDD support
that the responsiveness to dopaminergic medication is influenced
by the context. At preferred walking speed, three-arm swing
parameters correlated with LEDD values, at fast speed only one
and none during dual-tasking.
The changes in main arm swing amplitude, peak angular velocity,
and coordination with medication at preferred speed corresponds
with other studies investigating gait aspects in Parkinson’s
disease5,16,30. In previous studies, looking at gait parameters, it has
been seen that mainly the amplitude- and velocity-based measures
(step length, gait velocity, step velocity) improved with medication
at preferred speed, which is comparable to our results2,5–7,10. The
reduction in arm swing asymmetry found in this study corresponded
with one study16, but not with another which was probably due to
the inclusion of patients with dyskinesia in that study5. Other studies
also found effects of medication on gait parameters during more
challenging (fast) walking conditions7,9. Concerning more complex
walking paradigms contradicting results were found18,19. One study
even found a larger reduction in stride time variability with
medication during dual-tasking compared to single tasking19. Since
gait speed significantly changed between medication states and
single- and dual-tasking, these effects could very well be mediated
Fig. 1 Arm swing parameters during the different medication states and different walking conditions. a Main amplitude, b Peak angular
velocity, c Asymmetry of the amplitude, d Coordination between the arms, e Regularity of the angular velocity and f amplitude of the
sideways arm swing. * above horizontal lines, connecting different box plots = P < 0.05 between medication states. All data are corrected for
gait speed. Center line: median; box limits: upper and lower quartiles; whiskers: 1.5 × interquartile range.
Fig. 2 Responsiveness of the arm swing parameters and the
cognitive subtraction task to dopaminergic medication. A positive
standardized response mean (SRM) indicates an improvement with
medication and a negative SRM a worsening with medication. a
Walking at preferred speed, b Walking at fast speed and c Walking
with dual-task. 0.20 ≤ SRM < 0.50 represents a small, 0.50 ≤ SRM <
0.80 a moderate and SRM ≥ 0.80 a large responsiveness to
dopaminergic medication5. *significantly different from preferred
speed; #significantly different from fast speed/single-task condition.
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by gait speed. This issue holds also true for studies investigating arm
swing. To our knowledge, none of the currently available arm swing
studies controlled their results for gait speed, although it is known
that arm swing is influenced by this parameter24,31,32 and
dopaminergic medication increases gait speed6–8,11. In this study,
many significant Spearman’s correlations of arm swing parameters
with gait speed were found, with values reaching up to 0.47
(asymmetry, fast speed) for patients with Parkinson’s disease in OFF
medication state and up to 0.53 (main amplitude, dual tasking) for
patients with Parkinson’s disease in ON medication state. We
therefore recommend to perform this gait speed correction in future
studies, otherwise, there may be a risk that gait speed-associated
(and not disease state-associated) aspects are measured.
The cognitive performance increased with dopaminergic
medication in the single-task condition, but not in the dual-task
condition (Fig. 2). This effect was accompanied by significantly
more pronounced subtraction task dual-task costs in the
medication OFF state compared to the ON state. We interpret
these results according to already existing literature33,34 in that
way that, when patients with Parkinson’s disease perform a dual-
task in OFF state, they prioritize the cognitive task. This
prioritization of the cognitive task could have detrimental effects
on the walking performance.
In the dual-task condition, the cognitive performance, as well as
most arm swing parameters did not improve with dopaminergic
medication. A possible explanation for this could be the “levodopa
overdose hypothesis”35. Dopaminergic medication does not target
one specific brain area19. For example, it affects the mesocorti-
colimbic pathway, which has a negative effect on cognitive
function, including an executive function that is required to
control gait in patients with Parkinson’s disease19,36,37. This could
be a cause for the absent improvement in cognitive performance
and most arm swing parameters.
Although clinical assessments are in many aspects different
from daily living assessments38, studies have shown that more
complex clinical assessments correspond relatively well with the
average values of daily living assessments22,39. Our study shows
that the effect of dopaminergic medication on arm swing is rather
small or even negative during dual-tasking. This implies that
dopaminergic medication might, for this specific and potentially
very relevant movement40, not be very beneficial in real-life
situations. For handwriting, it also has been shown that
dopaminergic medication had no effect on the more complex
writing tasks, compared to writing down letters or one word
repeatedly in patients with Parkinson’s disease41. We can thus
confirm these findings with another upper limb movement (arm
swing), and contribute evidence that the effect of dopaminergic
medication should not only be tested under standardized
conditions but absolutely must also be tested under daily-
relevant situations. It seems possible that these medication effects
differ substantially between supervised and daily-life (-relevant)
conditions, and to a significant disadvantage for affected patients.
The even negative effect of dopaminergic medication on sideways
amplitude during dual-tasking could indicate a decrease in
dynamic postural stability with dopaminergic medication, which
must certainly be investigated in more detail in future studies.
Nevertheless, it is possible that the difference in dopaminergic
responsiveness due to different walking conditions affects not
only the upper but also the lower extremities. During simple static
postural stability tasks a positive effect of dopaminergic medica-
tion was found5,42, when more complex (eyes closed and dual-task
conditions) static postural stability tasks were performed there
was no effect of dopaminergic medication found43. During
dynamic postural stability tasks there were also no effects of
dopaminergic medication found and in the PIGD subgroup the
postural stability even frequently deteriorated with medication1,44.
Therefore, it seems that dopaminergic medication does not
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this phenomenon could also be seen in other neurotransmitter
systems. During preferred speed and simple dual-task walking
conditions, patients with Parkinson’s disease, treated with the
cholinesterase inhibitor rivastigmine, had a significantly better
(reduced) step time variability compared to the placebo-treated
group in a simple walking paradigm but there were no significant
differences found between the two groups during a complex dual-
task walking condition45.
None of the ON-OFF changes of arm swing parameters correlated
significantly with respective changes of the total MDS-UPDRS III score.
This observation strongly argues that arm swing is a movement that is
largely independent of “classic” Parkinson’s disease symptoms. This is
all the more remarkable as there was no effect observed in any of the
three different walking conditions. If this observation can also be
confirmed in larger independent studies and cohorts, and this effect is
potentially also shown in free-living environments, arm swing
parameters in Parkinson’s disease could be used as an easily and
frequently detectable complementary sign for disease progression
and treatment response in clinical routine and clinical trials. Moreover,
there was a positive correlation between the rigidity subscore and
sideways amplitude in the preferred walking speed condition (and
somewhat less pronounced and not significant in the dual-task
walking condition). Rigidity causes the absence or reduction of trunk
rotations. Rotations of the thorax are known to contribute to arm
swing46, therefore with decreased trunk rotations a smaller arm swing
amplitude, in both main and sideways direction, was expected. This
was, however, not the case for the sideways amplitude. It seems
plausible that, due to rigidity, the trunk can contribute less to balance
recovery during walking in PD. Consequently, sideways arm swing
could serve as a compensatory movement to recover from balance
perturbations. To determine whether the sideways amplitude is a
parameter for (limitations of) dynamic balance, further research is
required. The other significant (negative) correlation observed was
between the PIGD items and arm swing coordination during dual-task
walking. The postural instability and gait problems could cause a
more unstable gait pattern and the arms might be used to
compensate for any balance disturbances. Compensatory movements
of the arms might negatively influence the timing between the left
and right arm. The postural instability can especially be prominent
during dual-tasking where patients prioritize the cognitive perfor-
mance causing a decrease in postural stability according to the
“posture second” strategy33. This significant negative correlation could
speak for the usefulness of this parameter for determining the
severity of (and therapy response to) PIGD symptoms, e.g., under
everyday conditions39.
This study faces limitations. First, participants performed both OFF
and ON assessments on the same day and always OFF before ON,
therefore fatigue is a possible confounder in this study. However, all
study participants were allowed to take breaks at any time during
the individual task performance. Second, only patients with mild to
moderate disease severity were included, which means that the
results cannot be extrapolated to more advanced disease stages.
Taken together, this study shows that the responsiveness of
dopaminergic medication on arm swing in people with Parkin-
son’s disease depends on the context and task complexity. These
results should motivate more granular and extensive research in
the area of task complexity-influenced responsiveness of mobility
aspects to dopaminergic medication in Parkinson’s disease.
METHODS
Participants
Forty-five patients with a diagnosis of Parkinson’s disease according to the
UK Brain Bank Society Criteria47 and a Hoehn & Yahr stage between one
and three (reflecting mild to moderate disease severity) were recruited at
the University Hospital of Tübingen, Germany. Patients with an impaired
range of motion of the shoulder due to trauma were excluded as well as
patients with dyskinesia, because dyskinesia most probably has a
significant and “uncontrollable” influence on gait parameters5.
The ethical committee of the Medical Faculty of the University of Tübingen
approved this study (715/2011B02). All participants gave a written informed
consent prior to testing according to the declaration of Helsinki.
Data collection
Participants walked a 20m walkway up and down for 1 min, under three
conditions: (i) preferred speed (“Walk at your preferred walking speed”), (ii)
fast speed (“Please walk as fast as you can, do not run, do not risk falling”),
and (iii) fast speed in combination with a serial subtraction task started
from a three-digit number (“Please walk as fast as you can, do not run, do
not risk falling, and subtract serial sevens as fast as you can from the
number I will shortly tell you”). This serial subtraction task was also
separately performed as single-task. All participants performed the
assessments first OFF medication (overnight withdrawal from dopaminer-
gic medication) and 30min to 2 h after medication intake (based on the
participant’s feedback when they usually experience best ON) in ON
medication condition. In both medication states the motor part of the
MDS-UPDRS, part III, was assessed. The MDS-UPDRS part II was also
assessed, but only assessed once. The dopaminergic medication the
patients took was collected from the medical file to calculate the LEDD48.
During the assessments, all participants wore an inertial measurement unit
with tri-axial accelerometers, gyroscopes, and a magnetometer (128 Hz
sample frequency; Opal APDM, Portland, USA) on each wrist and one on
the lower back.
Data processing
All completed straight walking phases of the 1min walk were extracted
(turns were discarded from the data with help of a turn detection
algorithm validated for patients with Parkinson’s disease and healthy older
adults49). The gait speed was calculated by dividing the 20m walked
distance by the time it took to walk those 20m (based on the turn
detection described above). The arm swing parameters from the straight
walking phases were extracted with an arm swing algorithm validated for
patients with Parkinson’s disease and healthy adults23. Arm swing was
defined as “a rotational movement of the arm, occurring during walking
and running in bipeds with a periodicity of around 1–2 Hz. The hand and
arm move freely through space in opposite directions with most of the
movement in the sagittal plane of the body frame”23. To omit false
positives, only arm swings with an amplitude of at least five degrees were
taken into account23. The first three and last three swings of the straight
walking phases were excluded from the analysis so that only steady-state
walking phases were considered.
The arm swing algorithm extracts information from both arms, which
results in the following parameters (Table 4): main amplitude (amplitude in
main swing direction), peak angular velocity, regularity, coordination, and
asymmetry23. We also included in this analysis sideways amplitude,
reflecting the amplitude of the movement during the swing in the
direction orthogonal to the main swing direction (movements around the
longitudinal axis are not taken into account). Sideways arm swing could be
a compensatory movement to get the center of mass back above the base
of support. This movement therefore may reflect, as a measure of dynamic
postural stability, correction, or adaptation movements during walking50.
The parameter was calculated from the second component of the principal
component analysis23. The dual-task costs for the cognitive serial
subtraction task were calculated for both medication states34.
Statistical analysis
Since arm swing is affected by gait speed24,31,32, the parameters were
corrected for this parameter using a linear regression between gait speed
and each arm swing parameter per condition and per (medication) group.
All parameters were corrected to their estimated value at 1 m/s. Wilcoxon
signed-rank tests were used to analyse the effects of dopaminergic
medication on the arm swing parameters. Tests were two-tailed with a
significance level of 0.05.
To analyse the effect of medication on the cognitive performance during
single-tasking and dual-tasking Wilcoxon signed-rank tests were per-
formed. As well as for the effect of medication on the dual-task costs.
The standardized response mean (SRM) was calculated by dividing the
average of the change (xchange) by the standard deviation of the change in
E. Warmerdam et al.
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N represents the amount of participants and xi the arm swing parameter
of each participant in ON or OFF state, with 0.20 ≤ SRM < 0.50 representing
a small, 0.50 ≤ SRM < 0.80 a moderate and SRM ≥ 0.80 a large responsive-
ness to dopaminergic medication5.
The significances of dopaminergic medication effects between the three
walking conditions were analysed with a repeated measures ANOVA. A
Greenhouse-Geisser correction was performed when the assumption of
sphericity was violated. P < 0.05 was considered significant. Post hoc
testing was performed with Bonferroni corrections to control for type 1
errors.
Spearman correlations were performed to test associations between ON-
OFF effects of arm swing parameters and clinical scores (total MDS-UPDRS
III, and MDS-UPDRS subscores: bradykinesia (items 3.4, 3.5, 3.6, 3.851),
rigidity (item 3.3), tremor (items 2.10, 3.15, 3.16, 3.17, 3.1852), and PIGD
(items 2.12, 2.13, 3.10, 3.11, 3.1253), and LEDD. Significance of these
exploratory analyses was considered when P < 0.05.
Reporting Summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data from this study are available upon reasonable request.
CODE AVAILABILITY
The algorithm to extract the arm swing parameters can be accessed and downloaded
online (https://github.com/EWarmerdam/ArmSwingAlgorithm)23. The algorithm was
developed with Matlab 2017a.
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